Abstract
Chronic pressure overload, such as that with hypertension, induces left ventricular (LV) remodeling characterized by increased mass, that is, LV hypertrophy (LVH). LVH can cause impaired diastolic function and thereby contribute to heart failure. The myocardial extracellular matrix undergoes significant remodeling in LVH contributing to abnormalities in diastolic function. Current pharmacological strategies for the treatment of hypertension only indirectly and/or incompletely affect the structure and composition of the myocardial matrix. Identifying crucial pathways involved in matrix remodeling in hypertension-induced LVH will aid in the selection of more relevant targets.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 253-258 |
| Number of pages | 6 |
| Journal | Drug Discovery Today: Therapeutic Strategies |
| Volume | 2 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2005 |
| Externally published | Yes |
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
- Drug Discovery
Fingerprint Dive into the research topics of 'Targeting matrix remodeling in cardiac hypertrophy and heart failure'. Together they form a unique fingerprint.
Cite this
Lindsey, M. L., & Spinale, F. G. (2005). Targeting matrix remodeling in cardiac hypertrophy and heart failure. Drug Discovery Today: Therapeutic Strategies, 2(3), 253-258. https://doi.org/10.1016/j.ddstr.2005.08.001